These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2982278)

  • 1. Inhibition of sarcolemmal Na+-K+-ATPase by palmitoyl carnitine: potentiation by propranolol.
    Kramer JH; Weglicki WB
    Am J Physiol; 1985 Jan; 248(1 Pt 2):H75-81. PubMed ID: 2982278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of palmitoyl carnitine on Na+, K+-ATPase and adenylate cyclase activity of canine myocardial sarcolemma.
    Abe M; Yamazaki N; Suzuki Y; Kobayashi A; Ohta H
    J Mol Cell Cardiol; 1984 Mar; 16(3):239-45. PubMed ID: 6325716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac sarcolemmal Na+-K+-ATPase: combined effects of propranolol and arachidonyl CoA.
    Kramer JH; Owens K; Weglicki WB
    Am J Physiol; 1983 May; 244(5):H738-42. PubMed ID: 6303134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of palmitoyl carnitine and LPC on cardiac sarcolemmal Na+-K+-ATPase.
    Pitts BJ; Okhuysen CH
    Am J Physiol; 1984 Nov; 247(5 Pt 2):H840-6. PubMed ID: 6093598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fatty acid intermediates on Na+-K+-ATPase activity of cardiac sarcolemma.
    Owens K; Kennett FF; Weglicki WB
    Am J Physiol; 1982 Mar; 242(3):H456-61. PubMed ID: 6278956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perturbations of sarcolemmal and microsomal enzymes by amphiphilic lipids and drugs.
    Weglicki WB; Kramer JH; Kennett FF; Knauer TE; Owens K
    Adv Myocardiol; 1985; 6():127-36. PubMed ID: 2986257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of lipid intermediates on Ca2+ and Na+ permeability and (Na+ + K+)-ATPase of cardiac sarcolemma. A possible role in myocardial ischemia.
    Lamers JM; Stinis HT; Montfoort A; Hülsmann WC
    Biochim Biophys Acta; 1984 Jul; 774(1):127-37. PubMed ID: 6329291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of palmitoyl carnitine with calcium antagonists in myocytes.
    Patmore L; Duncan GP; Spedding M
    Br J Pharmacol; 1989 Jun; 97(2):443-50. PubMed ID: 2474346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of free radical-induced lipid peroxidative injury to sarcolemmal membranes by lipid amphiphiles.
    Mak IT; Kramer JH; Weglicki WB
    J Biol Chem; 1986 Jan; 261(3):1153-7. PubMed ID: 3003057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exogenous palmitoyl carnitine and membrane damage in rat hearts.
    Busselen P; Sercu D; Verdonck F
    J Mol Cell Cardiol; 1988 Oct; 20(10):905-16. PubMed ID: 3216401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of palmitylcarnitine on ouabain binding to Na, K-ATPase.
    Adams RJ; Pitts BJ; Woods JM; Gende OA; Wallick ET; Schwartz A
    J Mol Cell Cardiol; 1979 Oct; 11(10):941-59. PubMed ID: 230355
    [No Abstract]   [Full Text] [Related]  

  • 12. Palmitoyl carnitine increases intracellular calcium in adult rat cardiomyocytes.
    Netticadan T; Yu L; Dhalla NS; Panagia V
    J Mol Cell Cardiol; 1999 Jul; 31(7):1357-67. PubMed ID: 10403753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of palmitoyl CoA of EDTA- and Mg2+-ATPase of heavy meromyosin from rabbit skeletal muscle.
    Fujiwara A; Fujisaki H; Asai H; Yasumasu I
    J Biochem; 1981 Sep; 90(3):757-63. PubMed ID: 6118360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of some L-carnitine derivatives on heart membrane ATPases.
    Dhalla NS; Kolár F; Shah KR; Ferrari R
    Cardiovasc Drugs Ther; 1991 Feb; 5 Suppl 1():25-30. PubMed ID: 1851632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of propionyl L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction.
    Sethi R; Dhalla KS; Ganguly PK; Ferrari R; Dhalla NS
    Cardiovasc Res; 1999 Jun; 42(3):607-15. PubMed ID: 10533600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [M-cholinergic regulation of Na+,K+-ATPase activity of vesicular preparations of sarcolemma from the myocardium and intestinal smooth muscles].
    Danilenko MP; Smagulova ZSh; Turmukhambetova VK; Omarova RD; Esyrev OV
    Ukr Biokhim Zh (1978); 1988; 60(1):55-60. PubMed ID: 2834846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of acetylcholine on the Na+,K+-ATPase activity of different preparations of myocardial sarcolemma].
    Danilenko MP; Kum EA; Omarova RD; Esyrev OV
    Vopr Med Khim; 1983; 29(1):29-33. PubMed ID: 6301155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of a GTP-binding protein in coupling of a muscarinic cholinergic receptor and Na,K-ATPase in myocardial sarcolemma].
    Turmukhambetova VK; Danilenko MP; Panchenko MP; Ritov VB; Esyrev OV; Tkachuk VA
    Biokhimiia; 1992 Feb; 57(2):163-73. PubMed ID: 1326337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcolemmal Na(+)-K(+)-ATPase: inactivation by neutrophil-derived free radicals and oxidants.
    Kukreja RC; Weaver AB; Hess ML
    Am J Physiol; 1990 Nov; 259(5 Pt 2):H1330-6. PubMed ID: 2173423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of sarcolemma ATPases by some membrane-stabilizing drugs.
    Røed A; Brodal B
    Acta Pharmacol Toxicol (Copenh); 1981 Jan; 48(1):65-8. PubMed ID: 6261527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.